Twist Bioscience Corporation (TWST)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 90 | 132 | 204 | 245 | 313 | 377 | 432 | 456 |
| Operating profit | $m | -136 | -138 | ||||||
| Net profit | $m | -140 | -152 | -218 | -205 | -209 | -78 | -137 | -127 |
| EPS reported | $ | -1.30 | -2.22 | ||||||
| Operating cashflow per share | $ | -0.80 | -0.85 | ||||||
| Capex per share | $ | 0.47 | 0.64 | ||||||
| FCF per share | $ | -1.26 | -1.49 | ||||||
| Free cash flow | $m | -76 | -93 | ||||||
| Net debt | $m | -157 | -167 | ||||||
| Book value equity | $m | 473 | 446 | ||||||
| Book value per share | $ | 7.91 | 7.14 | ||||||
| Number of shares | m | 59.81 | 62.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.56 | 3.78 | ||||||
| P/S LTM | x | 4.47 | 3.90 | ||||||
| P/FCF LTM | x | -22.25 | -18.07 | ||||||
| EV/EBITDA LTM | x | -31.43 | -15.19 | ||||||
| EV/Sales LTM | x | 4.35 | 17.82 | ||||||
| Earnings Yield LTM | % | -4.61% | -1.77% | ||||||
| FCF Yield | % | -4.49% | -5.53% | ||||||
| Quality | |||||||||
| ROE | % | -16.42% | -29.89% | ||||||
| ROIC | % | -24.15% | -24.57% | ||||||
| Operating margin | % | -36.18% | -31.91% | ||||||
| Gross margin | % | +50.72% | +51.97% | ||||||
| FCF/Sales | % | -20.08% | -21.57% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +20.32% | +37.97% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.55 | -1.00 | ||||||
| Net Debt/EBITDA | x | 0.88 | 0.22 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +4.49% | +0.11% | ||||||
| Net debt/Equity | x | -0.33 | -0.37 | ||||||
| Gross debt/equity | x | 0.29 | 0.21 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Twist Bioscience Corporation (TWST)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free